Hayden Farquhar

Real-World Safety Profile of Xanomeline-Trospium (Cobenfy), the First Muscarinic Agonist Antipsychotic: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Preprint (version 2.0, six-quarter update: Q4 2024 to Q1 2026). First real-world post-marketing pharmacovigilance analysis of xanomeline-trospium (Cobenfy) in the FDA Adverse Event Reporting System, applying a four-method disproportionality battery, active-comparator analyses aga...